Genentech's Phase II Mmotion150 study for Tecentriq compared Tecentriq plus Avastin and Tecentriq monotherapy to sunitinib alone reinforced the potential of the combination drug for the treatment of patients with previously untreated, locally advanced or metastatic renal cell carcinoma. Read More »
Albertson’s Cos. have trained close to 3,000 pharmacists in administering naloxone to treat patients overdosing on opioids. Read More »
GlaxoSmithKline (GSK) and Innoviva Inc. recently released positive results for a study evaluating Relvar Ellipta in treating asthma. Read More »
Shire PLC's Natpar, an adjunctive treatment for adult patients with chronic hypoparathyroidism, was reviewed positively by the Committee for Medicinal Products for Human Use of the European Medicines Agency. Read More »
The Pharmaceutical Care Management Association (PCMA) has recommended that the next Food and Drug Administration (FDA) director adopt five specific strategies to encourage pharmaceutical pricing competition based on results of its recently commissioned report. Read More »
A collaboration to develop biomarker technology was announced by Bristol-Myers Squibb Co. and Nordic Bioscience last week. Read More »
Togo became the first country in Africa recognized by the World Health Organization for eliminating lymphatic filariasis, also known as elephantiasis, as a public health problem. Read More »
AbbVie has announced the successful results of an EXPEDITION-1 Phase III study that evaluated 12 weeks of treatment with glecaprevir/pibrentasvir (G/P). Read More »
New data on OCREVUS presented at American Academy of Neurology (AAN) annual meeting in Boston. Read More »
.jpg)
Shire's Vyvanse (lisdexamfetamine dimesylate) CII is now available in a chewable tablet formulation, making it the only Attention-Deficit/Hyperactivity Disorder and Binge Eating Disorder treatment available in five administration options. Read More »
The American Society of Health-System Professionals (ASHP) recently announced that Michael Cohen, operations officer for the investigations branch of the Department of Health and Human Services (HHS) Office of Inspector General (OIG) in Washington, D.C., believes clinicians need to not just look at opioids but also at non-controlled drugs when trying to understand drug abuse. Read More »
EMD Serono, the biopharmaceutical business of Merck KGaA and Pfizer Inc., recently announced that the Biologics License Application (BLA) for their avelumab drug was accepted for Priority Review by the U.S. Food and Drug Administration (FDA). Read More »
Incyte Corporation recently announced that it joined with the National Organization for Rare Disorders (NORD), the European Organization for Rare Disease (EURODIS) and more in recognizing Rare Disease Day 2017. Read More »
Amgen recently announced that a planned overall survival (OS) interim analysis of the Phase 3 head-to-head Endeavor trial delivered positive results. Read More »
Bracco Diagnostics, the U.S. subsidiary of Bracco Imaging, has had its Varibar Pudding product approved by the U.S. Food and Drug Administration. Read More »
The American Society of Health-System Professionals recently launched a pharmacy project aimed at training emergency medical services and law enforcement personnel on how to deliver naloxone to opioid-overdosed individuals. Read More »
Biologics Inc. has been selected by Lexicon Pharmaceuticals to provide limited distribution of the drug Xermelo. Read More »
.jpg)
Pfizer Inc. and nonprofit Population Services International recently announced a $1 million collaboration that will make it easier for people with hypertension in Myanmar and Vietnam to access medicine and treatment. Read More »
Genentech, along with the Breast International Group, Breast European Adjuvant Study Team and Frontier Science Foundation, recently reported positive results from the Phase III Aphinity study for combining Perjeta, Herceptin and chemotherapy in treating certain breast cancer patients. Read More »
McKesson Corp. and Change Healthcare Holdings Inc. have completed their agreement to build a new health care information technology company titled Change Healthcare. Read More »
Alerts Sign-up
